Rocket Lab's HASTE Is Flying Hypersonic Missions for the Pentagon. Here's the Defense Business Hiding Inside a Space Stock.

Rocket Lab’s HASTE hypersonic/suborbital test flights are targeted at the U.S. DoD to relieve a testing bottleneck, with per-flight contract value estimated at $9.5M–$22M versus $8M–$10M for standard Electron missions. The company has secured about $500M in HASTE contracts, including a $266M Space Force deal for 12 flights and a $190M Navy deal for 20 flights, with backlog equal to more than half of its projected 2026 revenue ($953M). Analysts expect Rocket Lab revenue to nearly triple from 2025 to 2028, supporting a modestly positive view despite the stock trading around 42x this year’s sales.

Analysis

HASTE is less a top-line step-change than a utilization and margin lever: Rocket Lab is turning the same manufacturing base into a higher-value defense testing product. The key second-order effect is financing optionality — steadier DoD cash flow lowers the probability that Neutron or adjacent platform investments require aggressive dilution, which is what matters for a story trading at a premium multiple.

The real competitive shift is away from legacy test infrastructure, not away from SpaceX. If hypersonic testing migrates from bespoke missiles and wind tunnels into outsourced launch-as-a-service, RKLB can become a toll collector on a budget line that was previously fragmented. That said, the moat is tactical, not permanent: defense primes and range operators can respond by bundling services, and DoD appropriations delays can make booked backlog look more durable than it is.

Contrarian view: the market may be overestimating backlog quality and underestimating execution friction. Defense launch revenue is milestone-driven, so a few slipped missions or a slower-than-expected ramp in HASTE cadence would pressure the multiple quickly. The thesis is 6-18 months, not days; near-term price action will likely track contract conversion, gross margin, and any Neutron timetable drift more than headline backlog growth.

Key Decisions for Investors

• Accumulate RKLB only on pullbacks or post-earnings weakness; use a 6-12 month horizon and exit if HASTE cadence or gross margin fails to inflect.
• Prefer RKLB 2027 call spreads over outright stock to express the HASTE/Neutron optionality while capping multiple-compression risk.
• Do not treat the HASTE backlog as revenue; make it a watch item and require evidence of conversion in quarterly bookings, launch cadence, and segment margin before adding risk.
• Set a downside alert on any Neutron delay or DoD budget slip; those are the cleanest falsifiers and would likely hit the stock faster than the contracts can de-risk it.